ArticleJournal of the National Cancer Institute2026
Mortality after emergency presentation: evidence from a cohort of 929 378 Medicare beneficiaries with common cancers diagnosed 2008-2017.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emergency diagnosis of multiple myeloma: a SEER-Medicare study.Cancer causes & control : CCC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEmergency presentation (EP) for cancer diagnosis is associated with higher mortality, but prior research has largely focused on select cancer types or non-U.S. populations. We estimated EP prevalence and associated mortality across 16 cancers in a national Medicare cohort.
methodsUsing SEER-Medicare data, we identified patients with 16 high-burden cancers diagnosed 2008-2017. EP was defined by an ED claim within 30 days before the index cancer claim and subtyped as inpatient EP (emergency hospitalization) or outpatient EP (following ED discharge). We estimated survival probabilities and mortality risk ratios (RRs) adjusted for demographics, tumor characteristics, comorbidity, frailty, and healthcare utilization.
resultsAmong 929,378 patients, 28% were EPs (22% inpatient, 6% outpatient). EP prevalence ranged from <10% (breast, prostate) to > 40% (liver, lung, stomach, colon, ovarian, pancreatic cancers). One-year survival was 81% for non-EPs, 60% for outpatient EPs, and 36% for inpatient EPs. Compared with non-EPs, inpatient EPs had nearly 4-fold higher 30-day adjusted mortality (RR = 3.88, 95% CI: 3.81-3.96), ranging from 2.1 (pancreas) to 6.3 (lymphoma). Among 90-day survivors, inpatient EPs had 51% higher one-year mortality (RR = 1.51, 1.49-1.52), ranging from 1.1 (pancreas) to 2.1 (lymphoma). Outpatient EPs showed intermediate risk (one-year mortality RR = 1.28, 1.26-1.30).
conclusionEP is common and predicts persistently elevated mortality in older U.S. adults after comprehensive covariate adjustment. Associations were strongest for cancer types underrepresented in prior research, including hematologic malignancies, breast, prostate, and bladder cancers. Routine EP monitoring could improve risk stratification at diagnosis and guide efforts to reduce avoidable emergency presentations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.